Stocktoria
MBX Biosciences, Inc. MBX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-09-13
Chart by TradingView
3/9
Piotroski F — financial health
26.97
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Operating income | -$98.1M | -$68.2M | -$35.3M |
| Net income | -$87.0M | -$61.9M | -$32.6M |
| Operating cash flow | -$79.9M | -$54.7M | -$32.0M |
| Free cash flow | -$81.9M | -$55.6M | -$32.1M |
| Total assets | $385.1M | $268.5M | $84.2M |
| Total liabilities | $15.9M | $11.1M | $4.3M |
| Shareholders' equity | $369.2M | $257.4M | -$72.5M |
| Ratios | |||
| Return on assets | -22.6% | -23.1% | -38.7% |
| Return on equity | -23.6% | -24.1% | 44.9% |
| Current ratio | 24.62 | 24.19 | 21.26 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 26.97 (safe)
- Working capital / assets 0.95
- Retained earnings / assets -0.583
- EBIT / assets -0.255
- Equity / liabilities 23.191
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001776111 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.